11 – 20 of 39
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Infections in patients with mantle cell lymphoma
- Contribution to journal › Article
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
- Contribution to journal › Letter
-
Mark
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
- Contribution to journal › Article
-
Mark
Comparing visual inspection with acetic acid, with and without Lugol's Iodine for triage of HPV self-sample positive women in Ethiopia : a randomized controlled trial
- Contribution to journal › Article
-
Mark
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older
- Contribution to journal › Letter
-
Mark
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 – a Nordic Lymphoma Group study
- Contribution to journal › Article
-
Mark
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia☆
- Contribution to journal › Article
-
Mark
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial
- Contribution to journal › Article
- 2023
-
Mark
Secondary malignancies among mantle cell lymphoma patients
- Contribution to journal › Article
-
Mark
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
- Contribution to journal › Article